炎性关节疾病中的AA淀粉样变：系统综述

IF 4.6 2区医学 Q1 RHEUMATOLOGY

Seminars in arthritis and rheumatism Pub Date : 2025-06-06 DOI:10.1016/j.semarthrit.2025.152762

Binta SAVADOGO , Hanna FAHED , Jérémie SELLAM , Sophie GEORGIN-LAVIALLE , Bruno FAUTREL , Stéphane MITROVIC

{"title":"炎性关节疾病中的AA淀粉样变：系统综述","authors":"Binta SAVADOGO , Hanna FAHED , Jérémie SELLAM , Sophie GEORGIN-LAVIALLE , Bruno FAUTREL , Stéphane MITROVIC","doi":"10.1016/j.semarthrit.2025.152762","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>AA amyloidosis (AAA) is a complication of chronic inflammation; the burden is expected to decrease with recent therapies. We conducted a systematic review of the incidence, prevalence, mortality and response to treatment of inflammatory joint disease (IJD)-related AAA.</div></div><div><h3>Methods</h3><div>MEDLINE, EMBASE and Cochrane library databases were searched until October 2024. Selected studies were prospective and retrospective cohorts as well as case series (≥ 10 patients) of histologically proven AAA occurring in IJD.</div></div><div><h3>Results</h3><div>From 1094 articles identified, we included 33. Substantial heterogeneity among studies was observed. Most studies (75.8 %) were published before 2010. No clear trend was identifiable in AAA incidence and mortality during the last decades. AAA prevalence rates in rheumatoid arthritis ranged from 16.7 % to 25.2 % before 2010 and decreased to 0.7 % after 2010, which suggests a potential positive role of biologic therapies. Similarly, AAA prevalence rates in ankylosing spondylitis ranged from 6.1 % to 8.5 % before 2010 and 1.1 % to 1.3 % after 2010. Immunomodulating therapies (especially biologics) seemed to improve values of AAA biomarkers, such as glomerular filtration rate and serum amyloid A level.</div></div><div><h3>Conclusions</h3><div>Our work highlights the need for more recent and comprehensive population-based epidemiological data to decipher the actual IJD-related AAA burden.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"74 ","pages":"Article 152762"},"PeriodicalIF":4.6000,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"AA amyloidosis in inflammatory joint diseases: A systematic review\",\"authors\":\"Binta SAVADOGO , Hanna FAHED , Jérémie SELLAM , Sophie GEORGIN-LAVIALLE , Bruno FAUTREL , Stéphane MITROVIC\",\"doi\":\"10.1016/j.semarthrit.2025.152762\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>AA amyloidosis (AAA) is a complication of chronic inflammation; the burden is expected to decrease with recent therapies. We conducted a systematic review of the incidence, prevalence, mortality and response to treatment of inflammatory joint disease (IJD)-related AAA.</div></div><div><h3>Methods</h3><div>MEDLINE, EMBASE and Cochrane library databases were searched until October 2024. Selected studies were prospective and retrospective cohorts as well as case series (≥ 10 patients) of histologically proven AAA occurring in IJD.</div></div><div><h3>Results</h3><div>From 1094 articles identified, we included 33. Substantial heterogeneity among studies was observed. Most studies (75.8 %) were published before 2010. No clear trend was identifiable in AAA incidence and mortality during the last decades. AAA prevalence rates in rheumatoid arthritis ranged from 16.7 % to 25.2 % before 2010 and decreased to 0.7 % after 2010, which suggests a potential positive role of biologic therapies. Similarly, AAA prevalence rates in ankylosing spondylitis ranged from 6.1 % to 8.5 % before 2010 and 1.1 % to 1.3 % after 2010. Immunomodulating therapies (especially biologics) seemed to improve values of AAA biomarkers, such as glomerular filtration rate and serum amyloid A level.</div></div><div><h3>Conclusions</h3><div>Our work highlights the need for more recent and comprehensive population-based epidemiological data to decipher the actual IJD-related AAA burden.</div></div>\",\"PeriodicalId\":21715,\"journal\":{\"name\":\"Seminars in arthritis and rheumatism\",\"volume\":\"74 \",\"pages\":\"Article 152762\"},\"PeriodicalIF\":4.6000,\"publicationDate\":\"2025-06-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Seminars in arthritis and rheumatism\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0049017225001337\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"RHEUMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in arthritis and rheumatism","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0049017225001337","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

背景：aa淀粉样变性（AAA）是慢性炎症的并发症；随着最近的治疗，这种负担有望减轻。我们对炎症性关节病（IJD）相关aaa的发病率、患病率、死亡率和治疗反应进行了系统回顾。方法检索medline、EMBASE和Cochrane图书馆数据库，检索截止到2024年10月。选择的研究包括前瞻性和回顾性队列以及组织学证实的IJD发生AAA的病例系列（≥10例患者）。结果从1094篇文献中纳入33篇。研究中观察到大量的异质性。大多数研究（75.8%）发表于2010年之前。在过去的几十年里，AAA的发病率和死亡率没有明显的趋势。类风湿性关节炎的AAA患病率在2010年前为16.7% - 25.2%，2010年后降至0.7%，这表明生物治疗具有潜在的积极作用。同样，强直性脊柱炎的AAA患病率在2010年前为6.1% - 8.5%，2010年后为1.1% - 1.3%。免疫调节疗法（尤其是生物制剂）似乎改善了AAA生物标志物的价值，如肾小球滤过率和血清淀粉样蛋白A水平。结论我们的工作强调需要更多最新和全面的基于人群的流行病学数据来解释实际的ijd相关的AAA负担。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

AA amyloidosis in inflammatory joint diseases: A systematic review

Background

AA amyloidosis (AAA) is a complication of chronic inflammation; the burden is expected to decrease with recent therapies. We conducted a systematic review of the incidence, prevalence, mortality and response to treatment of inflammatory joint disease (IJD)-related AAA.

Methods

MEDLINE, EMBASE and Cochrane library databases were searched until October 2024. Selected studies were prospective and retrospective cohorts as well as case series (≥ 10 patients) of histologically proven AAA occurring in IJD.

Results

From 1094 articles identified, we included 33. Substantial heterogeneity among studies was observed. Most studies (75.8 %) were published before 2010. No clear trend was identifiable in AAA incidence and mortality during the last decades. AAA prevalence rates in rheumatoid arthritis ranged from 16.7 % to 25.2 % before 2010 and decreased to 0.7 % after 2010, which suggests a potential positive role of biologic therapies. Similarly, AAA prevalence rates in ankylosing spondylitis ranged from 6.1 % to 8.5 % before 2010 and 1.1 % to 1.3 % after 2010. Immunomodulating therapies (especially biologics) seemed to improve values of AAA biomarkers, such as glomerular filtration rate and serum amyloid A level.

Conclusions

Our work highlights the need for more recent and comprehensive population-based epidemiological data to decipher the actual IJD-related AAA burden.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Seminars in arthritis and rheumatism 医学-风湿病学

CiteScore

9.20

自引率

4.00%

发文量

176

审稿时长

46 days

期刊介绍： Seminars in Arthritis and Rheumatism provides access to the highest-quality clinical, therapeutic and translational research about arthritis, rheumatology and musculoskeletal disorders that affect the joints and connective tissue. Each bimonthly issue includes articles giving you the latest diagnostic criteria, consensus statements, systematic reviews and meta-analyses as well as clinical and translational research studies. Read this journal for the latest groundbreaking research and to gain insights from scientists and clinicians on the management and treatment of musculoskeletal and autoimmune rheumatologic diseases. The journal is of interest to rheumatologists, orthopedic surgeons, internal medicine physicians, immunologists and specialists in bone and mineral metabolism.